Our PRODUCT
Natural Killer Cell Immunotherapies
ImmuneBridge is developing allogeneic, off-the-shelf cellular immunotherapies, starting with natural killer (NK) cell-based immunotherapies. Originating from CD34+ hematopoietic stem cells (HSCs), NK cells have a unique ability to recognize and attack tumor cells in healthy immune systems and initial data suggest they are a promising cellular path for safe, scalable next-generation immunotherapies.
Our Process
Screen the segment;
Translate the cord
ImmuneBridge’s proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency—to create a diverse, consistent, and abundant cellular source for immunotherapies, rooted in the immune lineage, but with the scalability of iPSCs. We are able to screen and select the best allogeneic sources for optimal phenotype.
OUR PLATFORM
ImmuneBridge Cellular Discovery Platform
The ImmuneBridge Cellular Discovery Platform combines the unique benefits of cord blood and our expansion technology to enable robust screening and selection for the most potent cancer-fighting cells. The Cellular Discovery Platform reduces costs of discovery and manufacturing, thereby expanding commercially viable indications for immunotherapy.
The Cellular Discovery Platform is available to collaborators and partners committed to our mission of making cell therapies accessible to all.